加科思药业集团有限公司（01167）于2026年3月16日公告，基于此前购回授权进行股份购回。公司当日于香港联交所回购39,000股普通股，占该日公司现有已发行股份数目的约0.005%，每股最高回购价为7.04港元、最低回购价为7港元，合计耗资274,029港元。
回购完成后，公司已发行股份总数降至786,633,780股，库存股份数目上升至5,121,300股。公司购回授权于2025年6月10日获得批准，授权范围内可购回的股份总数为78,873,528股，截至目前已有2,101,500股在交易所或其他证券交易所完成回购。公司强调本次回购符合香港联交所证券上市规则及相关法例的要求。
该公告由公司董事王晓洁签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.